Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

NT5c1A Antibodies in Motor Neuron Disease
Neuromuscular and Clinical Neurophysiology (EMG)
P9 - Poster Session 9 (12:00 PM-1:00 PM)
1-003
To describe the clinical features and electrodiagnostic findings of three patients with motor neuron disease and serum positive NT5c1A antibodies.
NT5c1A antibodies are common in inclusion body myositis and are associated with prominent bulbar, facial and respiratory involvement. NT5c1a antibodies been reported to have a sensitivity up to 70% and a specificity up to 92% in the diagnosis of inclusion body myositis. NT5c1A antibodies have also been associated with Sjogren’s syndrome and systemic lupus erythematosus. 
A retrospective chart review of three patients with serum positive NT5C1A antibodies and an eventual diagnosis of motor neuron disease in the Neuromuscular Clinic at University of California Irvine. 
Patient 1 was a 69 year old woman with a two year history of progressive weakness with initial symptoms of left foot drop, progressing to dysphagia and wheelchair dependence. Exam was notable for bilateral lower extremity atrophy, asymmetric lower extremity weakness, lower extremity fasciculations, and hyperreflexia. Patient 2 was an 80 year old man with a two year history of progressive painless weakness in his hands. Exam was notable for marked bilateral atrophy in the thenar eminence, rare fasciculations in the proximal upper extremities, asymmetric proximal and distal weakness, and hyperreflexia. Patient 3 was a 70 year old man with an 18 month history of asymmetric weakness with initial symptoms of left foot drop progressing to wheelchair dependence. Exam was notable for diffuse atrophy, fasciculations, proximal and distal extremity weakness,  and absent reflexes. Electrodiagnostic testing in all three patients showed evidence of ongoing chronic motor neuron changes in the cervical, thoracic, and lumbar regions.
NT5c1A antibodies can be seen in individuals with motor neuron disease in addition to systemic lupus erythematosus, Sjogren’s syndrome, and inclusion body myositis. Further studies may be beneficial to determine the frequency of NT5c1A antibodies in a motor neuron disease population. 
Authors/Disclosures
Michael C. Hunter, MD (Intermountain Healthcare)
PRESENTER 		Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hunter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen.
Manisha Kak Korb, MD Dr. Kak Korb has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Kak Korb has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. Dr. Kak Korb has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Kak Korb has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
Ali A. Habib, MD (University of California, Irvine) Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NMD Pharma. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon/ Amgen. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jansen/Johnson & Johnson. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMDSerono/Merck. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunis Biomedical. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman-La Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jansen/Joohnson & Johnson. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from Horizon/Amgen. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Regeneron. The institution of Dr. Habib has received research support from Arcellx. The institution of Dr. Habib has received research support from Novartis. The institution of Dr. Habib has received research support from EMDSerono/Merck. The institution of Dr. Habib has received research support from Cour Pharmaceuticals.